Sean Spring
YOU?
Author Swipe
View article: Data from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens
Data from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Open
This study examined the ability of a papillomavirus-like particle drug conjugate, belzupacap sarotalocan (AU-011), to eradicate subcutaneous tumors after intravenous injection and to subsequently elicit long-term antitumor immunity in the …
View article: Figure S7 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens
Figure S7 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Open
Role of CD4+ and CD8+ T-cells at the time of treatment and at the time of re-challenge.
View article: Figure S8 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens
Figure S8 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Open
Gating examples for MHC Class I H-2Db-E749-57 tetramer staining (A) and intracellular cytokine staining after PBMC re-stimulation (B) shown in Figure 6. C) Unstained and Isotype controls for each data set.
View article: Figure S5 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens
Figure S5 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Open
Examples of gating strategy to determine proportions and viability of tumor infiltrating cell populations shown in Figure 4.
View article: Figure S1 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens
Figure S1 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Open
In vivo efficacy of AU-011.
View article: Figure S3 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens
Figure S3 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Open
AU-011 induced ROS activity, optimization and efficacy in other tumor models.
View article: Data from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens
Data from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Open
This study examined the ability of a papillomavirus-like particle drug conjugate, belzupacap sarotalocan (AU-011), to eradicate subcutaneous tumors after intravenous injection and to subsequently elicit long-term antitumor immunity in the …
View article: Figure S6 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens
Figure S6 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Open
Examples of AU-011 efficacy in other tumor survival models.
View article: Figure S1 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens
Figure S1 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Open
In vivo efficacy of AU-011.
View article: Figure S2 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens
Figure S2 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Open
Detection of immunogenic cell death markers on TC-1 cells.
View article: Figure S6 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens
Figure S6 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Open
Examples of AU-011 efficacy in other tumor survival models.
View article: Figure S4 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens
Figure S4 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Open
Gating examples for the in vivo markers for AU-011 induced immunogenic cell death.
View article: Figure S3 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens
Figure S3 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Open
AU-011 induced ROS activity, optimization and efficacy in other tumor models.
View article: Figure S2 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens
Figure S2 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Open
Detection of immunogenic cell death markers on TC-1 cells.
View article: Figure S7 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens
Figure S7 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Open
Role of CD4+ and CD8+ T-cells at the time of treatment and at the time of re-challenge.
View article: Figure S4 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens
Figure S4 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Open
Gating examples for the in vivo markers for AU-011 induced immunogenic cell death.
View article: Figure S5 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens
Figure S5 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Open
Examples of gating strategy to determine proportions and viability of tumor infiltrating cell populations shown in Figure 4.
View article: Figure S8 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens
Figure S8 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Open
Gating examples for MHC Class I H-2Db-E749-57 tetramer staining (A) and intracellular cytokine staining after PBMC re-stimulation (B) shown in Figure 6. C) Unstained and Isotype controls for each data set.
View article: Data from An Infrared Dye–Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma
Data from An Infrared Dye–Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma Open
The work outlined herein describes AU-011, a novel recombinant papillomavirus-like particle (VLP) drug conjugate and its initial evaluation as a potential treatment for primary uveal melanoma. The VLP is conjugated with a phthalocyanine ph…
View article: Figures S1-S7 merged from An Infrared Dye–Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma
Figures S1-S7 merged from An Infrared Dye–Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma Open
Figure S1-video composites of real time AU-011 mediated killing of 92.1MEL cells; Figure S2-Killing and binding comparison of free IR700 dye to VLP conjugated IR700 (AU-011) on HeLa and 92.1MEL cells; Figure S3-Demonstration of both the AU…
View article: Figures S1-S7 merged from An Infrared Dye–Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma
Figures S1-S7 merged from An Infrared Dye–Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma Open
Figure S1-video composites of real time AU-011 mediated killing of 92.1MEL cells; Figure S2-Killing and binding comparison of free IR700 dye to VLP conjugated IR700 (AU-011) on HeLa and 92.1MEL cells; Figure S3-Demonstration of both the AU…
View article: Data from An Infrared Dye–Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma
Data from An Infrared Dye–Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma Open
The work outlined herein describes AU-011, a novel recombinant papillomavirus-like particle (VLP) drug conjugate and its initial evaluation as a potential treatment for primary uveal melanoma. The VLP is conjugated with a phthalocyanine ph…
View article: Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in <i>mdx</i> mice
Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in <i>mdx</i> mice Open
Current therapies for Duchenne muscular dystrophy (DMD) use phosphorodiamidate morpholino oligomers (PMO) to induce exon skipping in the dystrophin pre-mRNA, enabling the translation of a shortened but functional dystrophin protein. This s…